by The Global Induced Pluripotent Stem Cells Market describes Cells that are derived from adult human cells which have been genetically reprogrammed to an embryonic stem cell-like state. The induced pluripotent stem cells (iPSCs) technology holds great promise for developing patient- and disease-specific stem cells for research, disease modeling, drug discovery, and regenerative medicine purposes without the ethical concerns associated with embryonic stem cells.
The Global Induced Pluripotent Stem Cells Market is estimated to be valued at US$ 1,595.4 MN in 2024 and is expected to exhibit a CAGR of 1.4% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Global Induced Pluripotent Stem Cells Market Demand are Takara Bio Inc., Thermo Fisher Scientific, Fujifilm Holdings Corporation, Astellas Pharma, Fate Therapeutics, Ncardia, ViaCyte, Cellular Dynamics International, Lonza, Blueprint Medicines and Other Prominent Players. The growing demand for regenerative medicines and stem cell therapeutics is driving the growth of the market. With increasing research and development activities in regenerative medicines, the demand for induced pluripotent stem cells (iPSCs) is also growing globally. Several companies are expanding their operations across different geographies to tap into new customer bases and boost the access of iPSC technologies.
Market key trends
One of the major trends in the Global Induced Pluripotent Stem Cells market is the increasing focus on developing customized iPSC disease models. Industry players are investing heavily in developing patient-specific and disease-specific iPSC models that can help gain deeper insights into disease pathology and accelerate the drug discovery process. While iPSC technologies hold potential in modeling various disease conditions, customizing iPSCs as per the genetic mutations of individual patients can provide a more realistic model for research. This trend is expected to pick up further momentum over the coming years
Porter’s Analysis
Threat of new entrants: Low barriers such as intellectual property protection make it difficult for new companies to enter this niche market.
Bargaining power of buyers: Individual buyers have low bargaining power compared to well-established biotech companies and academic research institutions.
Bargaining power of suppliers: A small number of specialized suppliers of critical inputs like growth factors give them significant bargaining power over buyers.
Threat of new substitutes: Despite rapid advances, no clearly superior alternatives to iPSC technology currently exist for developing cell-based therapies and disease models.
Competitive rivalry: Competition is high among a few large players pursuing both academic research applications and clinical translation of iPSC-derived treatments.
Geographical Regions
North America currently accounts for the largest share of the global iPSC market value, driven by substantial investments in regenerative medicine across pharmaceutical and biotech companies as well as academic medical centers and research institutes in the United States.
The Asia Pacific region is expected to experience the fastest growth over the forecast period due to an increasing focus on developing domestic iPSC capabilities and cell therapy manufacturing infrastructure in countries like China, Japan, and South Korea. Established academic hubs and growth of the biotech industry are fueling expanding iPSC research activities and commercialization efforts across the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
